Compare PSMT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | ADPT |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2005 | 2019 |
| Metric | PSMT | ADPT |
|---|---|---|
| Price | $169.53 | $24.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $181.50 | $29.81 |
| AVG Volume (30 Days) | 222.1K | ★ 2.3M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | 5.47 | ★ 63.89 |
| EPS | ★ 4.18 | N/A |
| Revenue | ★ $4,066,093,000.00 | $276,976,000.00 |
| Revenue This Year | $10.46 | $5.94 |
| Revenue Next Year | $11.62 | $22.42 |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | 12.33 | ★ 54.77 |
| 52 Week Low | $111.68 | $12.00 |
| 52 Week High | $199.84 | $30.74 |
| Indicator | PSMT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 37.90 |
| Support Level | $166.32 | $23.73 |
| Resistance Level | $177.50 | $26.51 |
| Average True Range (ATR) | 3.62 | 1.44 |
| MACD | 0.16 | -0.49 |
| Stochastic Oscillator | 46.79 | 0.43 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.